Columbus Circle Investors Has $46.75 Million Stake in Sarepta Therapeutics Inc (SRPT)
Columbus Circle Investors grew its position in Sarepta Therapeutics Inc (NASDAQ:SRPT) by 57.7% during the 1st quarter, HoldingsChannel reports. The fund owned 392,243 shares of the biotechnology company’s stock after buying an additional 143,552 shares during the quarter. Sarepta Therapeutics comprises about 1.2% of Columbus Circle Investors’ holdings, making the stock its 24th biggest position. Columbus Circle Investors’ holdings in Sarepta Therapeutics were worth $46,751,000 at the end of the most recent reporting period.
Other large investors have also recently modified their holdings of the company. Cornerstone Advisors Inc. purchased a new stake in shares of Sarepta Therapeutics in the third quarter valued at about $25,000. Quad Cities Investment Group LLC boosted its holdings in shares of Sarepta Therapeutics by 100.0% in the first quarter. Quad Cities Investment Group LLC now owns 400 shares of the biotechnology company’s stock valued at $48,000 after acquiring an additional 200 shares in the last quarter. Oppenheimer Asset Management Inc. purchased a new stake in shares of Sarepta Therapeutics in the fourth quarter valued at about $51,000. Larson Financial Group LLC purchased a new stake in shares of Sarepta Therapeutics in the fourth quarter valued at about $55,000. Finally, First Manhattan Co. purchased a new stake in shares of Sarepta Therapeutics in the first quarter valued at about $107,000. 95.68% of the stock is currently owned by institutional investors and hedge funds.
SRPT stock traded down $2.85 during trading on Monday, reaching $113.79. 1,189,531 shares of the company were exchanged, compared to its average volume of 1,330,941. The company has a market cap of $8.33 billion, a P/E ratio of -20.84 and a beta of 2.04. Sarepta Therapeutics Inc has a 52-week low of $74.51 and a 52-week high of $176.50. The company has a current ratio of 8.21, a quick ratio of 7.49 and a debt-to-equity ratio of 0.41.
SRPT has been the topic of several analyst reports. BTIG Research set a $190.00 target price on shares of Sarepta Therapeutics and gave the company a “buy” rating in a report on Friday, December 28th. Zacks Investment Research raised shares of Sarepta Therapeutics from a “hold” rating to a “buy” rating and set a $109.00 target price on the stock in a report on Monday, December 31st. HC Wainwright set a $267.00 price objective on shares of Sarepta Therapeutics and gave the stock a “buy” rating in a report on Friday, January 4th. Janney Montgomery Scott set a $200.00 price objective on shares of Sarepta Therapeutics and gave the stock a “buy” rating in a report on Tuesday, January 8th. Finally, Royal Bank of Canada reissued an “outperform” rating and set a $164.00 price objective on shares of Sarepta Therapeutics in a report on Thursday, January 17th. One research analyst has rated the stock with a sell rating, three have assigned a hold rating, twenty-six have issued a buy rating and one has assigned a strong buy rating to the company. The stock currently has an average rating of “Buy” and an average target price of $191.14.
In other Sarepta Therapeutics news, SVP David T. Howton sold 30,000 shares of Sarepta Therapeutics stock in a transaction dated Friday, February 1st. The shares were sold at an average price of $140.00, for a total transaction of $4,200,000.00. Following the completion of the transaction, the senior vice president now owns 31,196 shares in the company, valued at $4,367,440. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CFO Sandesh Mahatme sold 65,000 shares of Sarepta Therapeutics stock in a transaction dated Thursday, January 31st. The stock was sold at an average price of $130.23, for a total transaction of $8,464,950.00. Following the transaction, the chief financial officer now owns 14,118 shares of the company’s stock, valued at approximately $1,838,587.14. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 160,000 shares of company stock valued at $22,089,950. 7.90% of the stock is currently owned by company insiders.
Sarepta Therapeutics Company Profile
Sarepta Therapeutics, Inc focuses on the discovery and development of RNA-based therapeutics, gene therapy, and other genetic medicine approaches for the treatment of rare diseases. The company offers EXONDYS 51, a disease-modifying therapy for duchenne muscular dystrophy (DMD). Its products pipeline include Golodirsen, a product candidate that binds to exon 53 of dystrophin pre-mRNA, which results in exclusion or skipping of exon during mRNA processing in patients with genetic mutations; and Casimersen, a product candidate that uses phosphorodiamidate morpholino oligomer (PMO) chemistry and exon-skipping technology to skip exon 45 of the DMD gene.
Read More: Cash Flow Analysis in Stock Selection
Want to see what other hedge funds are holding SRPT? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Sarepta Therapeutics Inc (NASDAQ:SRPT).
Receive News & Ratings for Sarepta Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Sarepta Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.